Pancreatic cancer: Future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal Intergroup Pancreatic Cancer Task Force

Surgical Oncology Clinics of North America

Volumn 13, Issue 4, 2004, Pages 751-760

  Jafari, Mehrdad ^a   Abbruzzese, James L ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; G 17 DT; GASTRIN ANTAGONIST; GEFITINIB; GEMCITABINE; IRINOTECAN; LONAFARNIB; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; PELITINIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; REBIMASTAT; TANOMASTAT; TIPIFARNIB; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACNE; ANGIOGENESIS; BINDING AFFINITY; CANCER INHIBITION; CANCER SURVIVAL; CELL ACTIVATION; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; CORRELATION ANALYSIS; COVALENT BOND; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; ENZYME INHIBITION; FATIGUE; GENE MUTATION; HUMAN; HYPOXIA; IMMUNOTHERAPY; LOW DRUG DOSE; METASTASIS; MUSCULOSKELETAL DISEASE; NONHUMAN; ONCOGENE K RAS; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT PLANNING;

ADULT; ADVISORY COMMITTEES; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER CARE FACILITIES; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FORECASTING; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 4444358409     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2004.06.009     Document Type: Review

References (50)

1. A. Jemal, R.C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, and E. Ward Cancer Statistics, 2004 CA Cancer J Clin 54 2004 8 29
2. R.J. Geer, and M.F. Brennan Prognostic indicators for survival after resection of pancreatic adenocarcinoma Am J Surg 165 1993 68
3. J.E. Lim, M.W. Chien, and C.C. Earle Prognostic factors following curative resection for pancreatic carcinoma: a population-based, linked database analysis of 396 patients Ann Surg 237 2003 74
4. H.A. Burris, M.J. Moore, J. Anderson, M.R. Green, M.L. Rothenberg, and M.R. Modiano Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 1997 2403 2413
5. C. Louvet, T. Andre, P. Hammel, F. Selle, B. Landi, and S. Cattan Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM) Ann Oncol 12 2001 675 679
6. J.D. Berlin, P. Catalano, J.P. Thomas, J.W. Kugler, D.G. Haller, and A.B. Benson III Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol 20 2002 3270 3275
7. D.P. Ryan, M.H. Kulke, C.S. Fuchs, M.L. Grossbard, S.R. Grossman, and J.A. Morgan A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma Cancer 94 2002 97 103
8. P.A. Philip, M.M. Zalupski, V.K. Vaitkevicius, P. Arlauskas, R. Chaplen, and L.K. Heilbrun Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma Cancer 92 2001 569 577
9. G. Colucci, F. Giuliani, V. Gebbia, M. Biglierto, P. Rabitti, and G. Uomo Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale Cancer 94 2002 902 910
10. C.M. Rocha Lima, D. Savarese, H. Bruckner, A. Dudek, J. Eckardt, and J. Hainsworth Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer J Clin Oncol 20 2002 1182 1191
11. C. Louvet, T. Andre, G. Lledo, P. Hammel, H. Bleiberg, and C. Bouleuc Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study J Clin Oncol 20 2002 1512 1518
12. R.H. Hruban, A.D. van Mansfeld, G.J. Offerhaus, D.H. van Weering, D.C. Allison, and S.N. Goodman K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched PCR analysis and allele-specific oligonucleotide hybridization Am J Pathol 143 2 1993 5545 5554
13. A.A. Adjei Blocking oncogenic ras signaling for cancer therapy J Natl Cancer Inst 93 2001 1062 1074
14. P.J. Casey, P.A. Solski, C.J. Der, and J.E. Buss p21 ras is modified by a farnesyl isoprenoid Proc Natl Acad Sci U S A 86 1989 8323 8327
15. Lersch C, Van Cutsem E, Amado R, Ehninger G, Heike M, Kerr D, et al. Randomized phase II study of SCH66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas. Proceedings of the American Society of Clinical Oncology. 2001;vol 20, abstract 608.
16. S.J. Cohen, L. Ho, S. Ranganathan, J.L. Abbruzzese, R.K. Alpaugh, and M. Beard Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma J Clin Oncol 21 2003 1301 1306
17. E. Van Cutsem, H. van de Velde, P. Karasek, H. Oettle, W.L. Vervenne, and A. Szawlowski Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J Clin Oncol 22 8 2004 1430 1438
18. S.M. Sebti, and A.A. Adjei Farnesyltransferase inhibitors Semin Oncol 31 1 Suppl 1 2004 28 39
19. S.R. Bramhall, J.P. Neoptolemos, G.W. Stamp, and N.R. Lemoine Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma J Pathol 182 1997 347 355
20. T. Koshiba, R. Hosotani, M. Wada, Y. Miyamoto, K. Fujimoto, and J.U. Lee Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma Cancer 82 1998 642 650
21. S.R. Bramhall, A. Rosemurgy, P.D. Brown, C. Bowry, and J.A. Buckels Marimastat Pancreatic Cancer Study Group. Marimastat as first line therapy for patients with unresectable pancreatic cancer: a randomized trial J Clin Oncol 19 2001 3447 3455
22. S.R. Bramhall, J. Schulz, J. Nemunaitis, P.D. Brown, M. Baillet, and J.A. Buckels A double-blind placebo-controlled randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer Br J Cancer 87 Suppl 2 2002 161 167
23. M.J. Moore, J. Hamm, J. Dancey, P.D. Eisenberg, M. Dagenais, and A. Fields Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trial Group J Clin Oncol 21 2003 3296 3302
24. K.R. Hess, and J.L. Abbruzzese Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design J Clin Oncol 19 2001 3445 3446
25. C.L. Arteaga Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia Semin Oncol 29 2002 3 9
26. Y. Yamanaka, H. Friess, M.S. Kobrin, M. Buchler, H.G. Beger, and M. Korc Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness Anticancer Res 13 1993 565 569
27. J.D. Sato, T. Kawamoto, A.D. Le, J. Mendelsohn, J. Polikoff, and G.H. Sato Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors Mol Biol Med 1 1983 511 529
28. Z. Fan, and J. Mendelsohn Therapeutic application of anti-growth factor receptor antibodies Curr Opin Oncol 10 1998 67 73
29. J.P. Overholser, M.C. Prewett, A.T. Hooper, H.W. Waksal, and D.J. Hicklin Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice Cancer 89 2000 74 82
30. J. Mendelsohn Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy Clin Cancer Res 3 1997 2703 2707
31. J. Mendelsohn, and J. Baselga The EGF receptor family as targets for cancer therapy Oncogene 19 2000 6550 6565
32. Abbruzzese JL, Rosenberg A, Xiong Q, Lo Buglio A, Schmidt W, Wolff R, et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer [abstract #518]. Proceedings of the American Society of Clinical Oncology 2001;vol 20, abstract 518.
33. Saltz L, Kies M, Abbruzzese JL, Azarnia N, Needle M. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies [abstract #817]. Proceedings of the American Society of Clinical Oncology 2003;22:204.
34. Cunningham D, Humblet Y, Sienas S, Khayat D, Bleiberg H, Santoro, et al. Cetuximab (c225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth-factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) [abstract #252]. Proceedings of the American Society of Clinical Oncology 2003;22:252.
35. L.B. Saltz, N.J. Meropol, P.J. Loehrer Sr., M.N. Needle, J. Kopit, and R.J. Mayer Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 2004 1201 1208
36. X.D. Yang, X.C. Jia, J.R. Corvalan, P. Wang, and C.G. Davis Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy Crit Rev Oncol Hematol 38 2001 17 23
37. Meropol NJ, Berlin J, Hecht JR, Croghan GA, Patnaik A, Weiner LM, et al. Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer [abstract #1026]. Proceedings of the American Society of Clinical Oncology 2003;22:256.
38. Safran H, Ramanathan R, Schwartz J, King T, Steinhoff MM, Nauman C, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu [abstract #130]. Proceedings of the American Society of Clinical Oncology 2001;20, abstract 130.
39. Morgan A, Bukowski RM, Xiong H, Clark J, Zacharchuk C, Plazney D, et al. Preliminary report of a phase 1 study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), given in combination with gemcitabine to patients with advanced pancreatic cancer [abstract #788]. Proceedings of the American Society of Clinical Oncology 2003;22:197.
40. L.M. Greenberger, C. Discafani, Y.F. Wang, H-R Tsou, E.G. Overbeek, and R. Nilakantan EKB-569: a new irreversible inhibitor of epidermal growth factor receptor tyrosine kinase for the treatment of cancer [abstract #388] Proceedings of the 11th NCI-EORTC-AACR Symposium, Clinical Cancer Research Suppl, 2000 6
41. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 1971 1182 1186
42. A.C. Koong, V.K. Mehta, Q.T. Le, G.A. Fisher, D.J. Terris, and J.M. Brown Pancreatic tumors show high levels of hypoxia Int J Radiat Oncol Biol Phys 48 2000 919 922
43. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat Med 9 2003 669
44. S.E. Duff, C. Li, M. Jeziorska, S. Kumar, M.P. Saunders, and D. Sherlock Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy Br J Cancer 89 2003 426
45. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, and W. Heim Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
46. Kindler HL, Friberg G, Stadler WM, Singh D, Locker G, Nattam S, et al. Bevacizumab plus gemcitabine is an active combination in patients with advanced pancreatic cancer: interim results of an ongoing phase II trial from the University of Chicago Phase II Consortium [abstract #86]. Presented at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology. San Francisco, January 22, 2004.
47. Crane CH, Ellis LM, Xiong H, Ho L, O'Reilly M, Evans DB, et al. Preliminary results of a phase I study of rhuMab VEGF (bevacizumab) with concurrent radiotherapy (XRT) and capecitabine (CAP) [abstract #85]. Presented at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology. San Francisco, January 22, 2004.
48. J.P. Goeze, F.C. Nielsen, F. Burcharth, and J.F. Rehfeld Closing the gastrin loop in pancreatic carcinoma: coexpresssion of gastrin and its receptor in solid human pancreatic adenocarcinoma Cancer 88 2000 2487 2494
49. Gilliam AD, Henwood M, Watson SA, Rowlands B, Broome P, Beckingham L, et al. G17DT therapy may improve the survival of patients with advanced pancreatic carcinoma [abstract #533]. Proceedings of the American Society of Clinical Oncology 2001;vol 20, abstract 533.
50. B.T. Brett, S.C. Smith, C.V. Bouvier, D. Michaeli, D. Hochhauser, and B.R. Davidson Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer J Clin Oncol 20 2002 4225 4231